Leveling the Playing Field: Overcoming Barriers to Equitable Care in ILD


Yolanda Mageto, MD, MPH, ATSF
Section Lead, Interstitial Lung Disease Program
Advanced Heart and Lung Disease
Baylor University Medical Center, Baylor Scott and White Health
Dallas, TX
Yolanda Mageto, MD, MPH, ATSF

Yolanda Mageto, MD, MPH, ATSF, a pulmonary critical care specialist with nationally recognized expertise in interstitial lung disease (ILD), has assumed the role of Medical Director of Interstitial Lung Disease at Baylor University Medical Center at Dallas in Dallas, Texas. Dr. Mageto attended medical school at Washington University in St. Louis, Missouri, and completed her residency and training at University of Texas Southwestern and fellowship in pulmonary and critical care medicine at the University of Washington in Seattle with a focus in ILD. Since that time, she has held faculty positions at the University of Washington Seattle, University of Texas Southwestern, and, most recently, University of Vermont, where she rose to the rank of full professor. Dr. Mageto is a clinician, educator, and researcher involved in multiple idiopathic pulmonary fibrosis/ILD trials over last 20 years including collaborations with investigators from other centers in sarcoidosis-related lung disease. She remains actively involved in the total care and management of her patients. Dr. Mageto is dedicated to the development of a Comprehensive Integrated Interstitial Lung disease program, optimizing delivery of care to patients with ILD in the Dallas Fort Worth Area. In her spare time, she enjoys spending time with her family, travelling, reading a good book, and cooking.

Ayodeji Adegunsoye, MD, MS, FCCP
Assistant Professor of Medicine
Scientific Director, Interstitial Lung Disease Program
University of Chicago Medicine
Chicago, IL
Ayodeji Adegunsoye, MD, MS, FCCP

Dr. Ayodeji Adegunsoye is a pulmonary and critical care physician-scientist whose interests focus on the intersection between clinical risk-prediction models and genomic markers to improve pulmonary fibrosis outcomes.

Pulmonary fibrosis is a destructive interstitial lung disease characterized by profound scarring. In severe pulmonary fibrosis, death generally ensues within three to five years. Recent genomic advances have identified factors that influence heterogeneity and prognosis in pulmonary fibrosis. However, health care disparities and the exclusion of major racial groups from these genetic studies limits the generalizability of their findings. Dr. Adegunsoye’s work leverages advanced statistical techniques to improve the delivery of high-quality care in patients with fibrotic lung diseases. Much of his research is aimed at identifying improved practical strategies to optimize pharmacotherapy in patients with pulmonary fibrosis.

Currently, the main focus of Dr. Adegunsoye’s work is utilizing genetic data from a diverse patient population to improve clinical decision-making and outcomes for all patients with pulmonary fibrosis.

Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
New York-Presbyterian Hospital and Weill Cornell Medicine
New York, NY
Fernando J. Martinez, MD, MS

Fernando J. Martinez, MD, MS, is chief of the Division of Pulmonary and Critical Care Medicine at NewYork-Presbyterian Hospital and Weill Cornell Medicine in New York City. He received his medical degree from the University of Florida in Gainesville, Florida, and completed his internal medicine residency at Beth Israel Hospital/Harvard Medical School and fellowship in pulmonary and critical care medicine at Boston University in Boston, Massachusetts. Additionally, Dr. Martinez received a master’s degree in biostatistics and clinical study design from the University of Michigan School of Public Health in Ann Arbor, Michigan.

A premiere translational researcher in chronic lung disease, Dr. Martinez is nationally and internationally recognized for his seminal studies in phenotypic and functional classification, and clinical interventions in chronic obstructive pulmonary disease and interstitial lung disease. He has authored 282 peer-reviewed manuscripts, 32 review articles, and 32 book chapters. Dr. Martinez is a member of the American College of Chest Physicians, the American Thoracic Society, and the American Association of Cardiovascular and Pulmonary Rehabilitation.

Statement of Need

More than 200 interstitial lung diseases (ILD) — from rare to relatively common – are now recognized in the United States, with most forms characterized by inflammation or fibrosis within the interstitial space. While the past several years have brought significant advances in management, the timely implementation of contemporary diagnostic and therapeutic pathways has been inconsistent by clinicians, in part due to a lack of coordinated, multidisciplinary care. Moreover, disparities in screening and treatment for patients with ILD further impedes achievement of optimal clinical outcomes, including improved quality of life.

In this recorded webcast, case-based CME Outfitters activity, a panel of experts in ILD explores strategies for implementing equitable, multidisciplinary care for all patients with ILD. The critical roles of assessing social determinants of health, engaging in shared decision-making with patients, and evaluating potential implicit bias are among the topics covered in this important initiative.

Learning Objectives

  • Implement timely screening strategies that support accurate diagnosis, focused patient education, and appropriate referrals for patients with ILD.
  • Develop multidisciplinary treatment pathways for the care of patients with ILD that include lifestyle modifications, pharmacotherapies, referrals, and management of comorbidities.
  • Incorporate shared decision-making (SDM) with patients that factors in recognition of SDoH and equitable care opportunities.

Financial Support

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

Internists, primary care clinicians, pulmonologists, radiologists, infectious disease specialists, pathologists, nurse practitioners (NPs), physician associates (PAs), pharmacists, and other health care practitioners (HCPs) involved in the care and coordination of diverse populations of patients with ILD.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-071-H01-P

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Mageto reports the following financial relationships:

Advisory Board: Tvardi Therapeutics (Steering Committee)

Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc. Other financial or material Support: United Therapeutics Corporation (DSBM)

Dr. Adegunsoye reports the following financial relationships:

Advisory Board: AbbVie inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; Inogen, Inc.; and patientMpower.

Consultant: Boehringer Ingelheim Pharmaceuticals, Inc. and Medscape.

Grants: CHEST Foundation; National Institutes of Health (NIH); and Pulmonary Fibrosis Foundation.

Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.

Dr. Martinez reports the following financial relationships:

Advisory Board: Boehringer Ingelheim Pharmaceuticals, Inc.; Devpro Biopharma and GSK.

Consultant: AstraZeneca; Excalibur Pharmaceuticals; Lung Therapeutics; and Sanofi.

Research Support: ILD related SC for studies supported by Biogen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; DevPro Biopharma; Nitto Denko Corporation; and Roche.

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Rebecca Vargas-Jackson, MD (peer reviewer)
  • Meghann Taft-Lockard (planning committee)
  • Warren Beckman (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Leveling the Playing Field: Overcoming Barriers to Equitable Care in ILD
Event Date: 08/09/2023